Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.74 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.74 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.74 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.74 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333232 | 0.85 | NOTUM (1.00) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM | |
| SCHEMBL11982072 | 0.84 | CSNK2A2 (0.78) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM | |
| SCHEMBL16339247 | 0.76 | NOTUM (1.00) | CSNK2A2CSNK2BCSNK2A1NOTUMCTDSP1 | |
| SCHEMBL29370624 | 0.72 | CSNK2A2 (0.59) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM | |
| SCHEMBL7056588 | 0.69 | HTT (0.75) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM | |
| SCHEMBL15337878 | 0.69 | NOTUM (0.51) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM | |
| SCHEMBL29368679 | 0.66 | KDM4E (0.82) | CSNK2A2CSNK2BCSNK2A1NOTUMHTT | |
| SCHEMBL16339840 | 0.66 | NOTUM (1.00) | CSNK2A2CSNK2BCSNK2A1NOTUMCTDSP1 | |
| SCHEMBL439234 | 0.65 | FGFR1 (0.54) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM | |
| SCHEMBL14817521 | 0.64 | MAPK1 (0.50) | PLK1CSNK2A2CSNK2BCSNK2A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160011195-A1 | Method of Forming Fragment Ligated Inhibitors | UNIVERSITY OF SOUTH CAROLINA | 2016-01-14 | — | — | US | disclosed |
| US-20150315555-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA | 2015-11-05 | — | — | US | disclosed |
| US-9175357-B2 | Fragment ligated inhibitors selective for the polo box domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120202970-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315555-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | PLK1, POLD1, CTDSP1 | PLK1 1/4885CSNK2A2 2966/4885CSNK2B 1988/4885 |
| US-20160011195-A1 | Method of Forming Fragment Ligated Inhibitors | PLK1, POLD1, POLR1E | PLK1 1/4885CSNK2A2 2958/4885CSNK2B 1984/4885 |
| US-20120202970-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | PLK1, POLD1, CTDSP1 | PLK1 1/4885CSNK2A2 2966/4885CSNK2B 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.